In this study we localized more precisely the salivary glycoprotein-interacting and the human immunoglobulin G (hIgG)-cross-reacting domains on the SR molecule, an antigen I/Il-related protein from S. mutans serotype f. Mapping of the SR molecule with polypeptides expressed by subclones covering the entire molecule and with synthetic peptides demonstrates that the salivary glycoprotein-binding domain is located in the N-terminal alanine-rich repeats of the SR molecule. In order to investigate the degree of conservation of both regions in various oral streptococci, we tested the reactivity of 8 representative strains of the mutans group and 11 nonmutans oral Streptococcus strains (S. anginosus, S. milleri, S. consteUlatus, S. intermedius, S. mitis, S. sanguis, S. gordonii, S. salivarius, and S. mitis strains) with antipeptide antibodies in a whole-cell enzyme linked immunosorbent assay together with colony hybridization analysis using DNA probes designed to map these two regions. All the mutans group strains except S. rattus and the 11 nonmutans streptococcal strains showed a high conservation of the C-terminal part of the SR molecule, especially the hIgG-cross-reacting domain, and less homology for the N-terminal salivary glycoprotein-binding region. Almost all of the sera from patients with rheumatic disease reacted strongly with SR from S. mutans serotype f, PI from S. mutans serotype c, and four peptides located in the hIgG-cross-reacting region and not with peptides located at the C and N termini and in the proline-rich repeats. These results confirm that epitopes located within this region are immunogenic in humans and could lead to the synthesis of natural anti-IgG antibodies.
The oral cavity harbors several species of streptococci, mostly alpha-hemolytic, which colonize different sites in the mouth (7) . These streptococci possess a family of cell surface cross-reactive proteins, termed antigen I/Il (37) (equivalent to B [38] , IF [19] , P1 [13, 20] , SR [1, 32] , PAc [34, 35] , MSL-1 [11] , SpaA [17] , PAg [33, 45] , and SSP-5 [9] ), having a molecular mass of approximately 180 to 210 kDa. The large distribution of these proteins among the different oral species suggests that antigen I/II serves an important function for the bacteria and may be an important virulence factor in bacterial pathogenicity. Antigen I/II from Streptococcus mutans and Streptococcus sanguis (10, 27) plays an important role in the interactions between bacteria and salivary glycoproteins (SGPs) adsorbed on the tooth surfaces and may function as an adhesin (12, 16) . Structural analysis of cloned and sequenced genes for various adhesins showed a high degree of homology between them (22) , implying that the proteins are functionally related. These results are also consistent with the previously observed immunological cross-reactivity. Two regions of the adhesins, the alanine-rich N-terminal one-third and the middle proline-rich region, appear particularly well conserved both within and between species. Therefore, the presence of such conserved regions suggests that the functional domains could be conserved and the binding sites for SGPs may be formed by these two interspecies-conserved regions of antigen I/IH. Recently Brady et al. (5) showed that the N-terminal alanine-rich domain of protein P1 may be involved in strep-tococcal aggregation mediated by fluid-phase salivary agglutinin, whereas adherence to agglutinin-coated hydroxyapatite seems to be located in the middle and C-terminal regions. Moreover, Crowley et al. (8) demonstrated that the alaninerich region of protein P1 is an important domain which interacts directly with salivary agglutinin and that this interaction interferes with both the aggregation and the adherence mechanisms in vitro.
Furthermore, it has been suggested that some oral streptococcus species play a role in the pathogenesis of various autoimmune disorders (23, 43) , and antigen mimicry has been proposed as an explanation for the synthesis of autoantibodies. A previous immunological analysis of protein SR, an antigen I/II-related protein from S. mutans serotype f, has demonstrated that protein SR possesses epitopes in common with human immunoglobulin G2 (hIgG2) and hIgG4 (47) , and we showed recently the presence of high titers of anti-SR antibodies in sera from patients with rheumatic disease (RD) (2) . The anti-SR antibodies are principally IgG and react with the Fd part of the heavy chains, suggesting the possible role of protein SR in the synthesis of anti-IgG antibodies in RDs. Furthermore, a computer analysis of the complete amino acid sequence of the SR protein with these of the hIgG heavy chains has shown that the region of SR between residues 948 and 1028 has 25% sequence identity with the Cl region of the human y2 chain (amino acids [aa] 110 to 190) (14) . I/II-related antigens are considered valuable candidates for vaccination against dental caries; however, because of this side effect, it would be necessary to The aim of this study was to localize more precisely the SGP-interacting and the hIgG-cross-reacting domains on the SR molecule from S. mutans serotype f by using recombinant peptides covering the entire SR sequence and synthetic peptides, one located in the first alanine-rich repeated domain and four located in the putative hIgG-cross-reacting region. This was followed by examination of the existence of both domains in various oral strains of streptococci by using antipeptide antibodies and PCR probes, and finally we examined the reactivity of sera from patients with RD against the different peptides. Research, Sidney, Australia. E. coli transformed with the recombinant plasmids pHBsr-1, pSAD2, p18 D2.8, and p8 PP1.4 was grown in Luria-Bertani broth supplemented with ampicillin (50 pug/ml). Cellular extracts from transformants carrying either the three recombinant plasmids p18 D2.8, p8 PP1.4, and pSAD2 or only plasmids pUC 8 and pTZ 18R were prepared from E. coli cells as described by Ogier et al. (31) . hIgG was obtained from Sigma.
MATERIALS AND METHODS

Bacterial
Peptides. Peptides 2, 4, and 5 were described previously (14) . Peptides 7 and 8, located in the C-terminal part of the putative hIgG-cross-reacting region of protein SR, were synthesized by Neosystem (Strasbourg, France) according to the method of Merrifield (28) . The composition of the peptides was confirmed by amino acid analysis, and the purity (>85%) was checked by high-performance liquid chromatography. Tyrosine was added to the amino terminus of peptide 4 and to the carboxy terminus of peptide 8 in order to couple them to ovalbumin through bisdiazobenzidine. The peptides were also conjugated to bovine serum albumin (BSA) by using glutaraldehyde (3) . Positions of the five peptides along the SR protein as well as their sequences are given in Table 2 .
Immunization and preparation of antisera. Rabbit anti-SR, antipeptide, and anti-SGP sera were prepared as previously described (14, 31) . Briefly, antipeptide sera were raised in three rabbits each, by subcutaneous injections of an equal mixture of peptides conjugated to ovalbumin (100 pug of peptides in phosphate-buffered saline [PBS] ) and Freund's incomplete adjuvant at 15-day intervals. At least 400 pug of peptides was injected, and blood was collected 5 days after the last injection. The IgG fraction of each antiserum was purified by chromatography on DEAE-Trisacryl M essentially by the method of Corthier et al. (6) and then reconsti- (36) . Ten serum samples with IgM rheumatoid factor titers of <1/32 were used as controls.
ELISA. For the enzyme-linked immunosorbent assay (ELISA), microtiter plates (Nunc) were coated with 50 ,ul of either S. mutans or other bacterial species whole cells (109 bacteria per ml), SR or P1 (1 ,ug/ml), hIgG (1 ,ug/ml), or BSA-peptide (1 ,ug of peptide conjugated to BSA per ml) diluted in 0.1 M carbonate buffer (pH 9.6). After overnight incubation at 4°C, the plates were blocked with PBS containing 0.05% Tween 20 (PBST) and 0.5% gelatin.
The reactivity of rabbit IgG was tested as previously described (14) . Briefly, 50 ,ul of serial dilution in PBST of the purified IgG from the various antisera was added to the wells and incubated at 37°C for 1 h. Antibody binding was detected by incubation with AP-GAR IgG (1/10,000, 37°C, 1 h) followed by incubation with alkaline phosphatase substrate. (30) . Briefly, whole unstimulated saliva was collected on ice. The pooled saliva was centrifuged (10,000 x g, 20 min, 4°C) and heat inactivated at 56°C for 30 min. The SGP-binding activities of streptococci, SR, SR-derived polypeptides, and synthetic peptides were determined by a direct binding and a competitive binding solidphase assay (29) . Controls were used according to the method of Ogier et al. (30) .
In the direct binding assay, plates coated with either bacteria (109 cells per ml), SR (1 ,ug/ml), cellular extracts (10 ,ug/ml) or BSA-peptides (1 ,ug/ml) were successively incubated with serial dilutions of SGPs in PBST (37°C, 1 h) rabbit anti-SGP IgG (37°C, 1 h), AP-GAR IgG (37°C, 1 h), and alkaline phosphatase substrate (37°C, 1 h), and the A405 was read after incubation of these plates at 25°C for 1 h.
In the competitive assay, 25 ,ul of a minimal saturating amount of SGPs (40 ,ug/ml) per well was added to coated wells together with 25 ,ul of competitor concentrations ranging from 0.1 to 100 ,ug/ml and was left at 37°C for 1 h. After washing, bound salivary components were detected by successive incubations with rabbit anti-SGP IgG, AP-GAR IgG, and enzyme substrate, as described above. The percent inhibition of SGP binding was calculated as (1 -competitor A405/controlA405) x 100.
RESULTS
Choice, antigenicity, and immunogenicity of synthetic peptides. Alignment of amino acids sequences of the SR protein and human IgG2 heavy chain showed 25% primary sequence identity between aa 948 to 1028 of the SR protein and aa 110 to 190 of the Cl region of the human -y2 chain (14) . In order to confirm the localization of the predicted IgG-cross-reacting epitope(s), we selected peptides from the amino acid sequence of the SR protein for chemical synthesis and the production of antibodies (Table 2) . Peptide 2, located in the first alanine repeated region of SR, and peptides 4 and 5, in the N-terminal part of the hIgG-cross-reacting region, were previously described (14) . To determine more precisely the localization of the hIgG cross-reactive region, peptides 7 and 8, representing the C-terminal end of this region (aa 995 to 1027), were synthesized. The synthetic peptides were first used to establish the extent to which antibodies directed against these determinants are elicited in rabbits immunized with SR or hIgG. The five synthetic peptides reacted with anti-SR rabbit IgG in an ELISA, and anti-SR IgG showed a progressive decrease in binding with peptides 2, 5, 8, 7, and 4 and did not react with SR-unrelated control peptide ( Fig.  2A) . Anti-hIgG rabbit IgG bound strongly to peptides 8 and 5, moderately to peptide 4, and very weakly to peptide 7 and failed to react with peptide 2 and the SR-unrelated control peptide (Fig. 2B) . In control experiments, rabbit preimmune IgG and AP-GAR IgG failed to react with any of the peptides.
Synthetic peptides conjugated to ovalbumin were injected into rabbits in order to elicit antibodies and gave rise to sera 2, 4, 5, 7, and 8. After collection, sera were screened by ELISA for the presence of antibodies reactive against peptides (Fig. 3A) , SR (Fig. 3B) , native SR protein present on whole S. mutans cells (Fig. 3C) , and hIgG (Fig. 3D) . To ensure that the reactivity of antiserum measured in the ELISA was a peptide-specific response, plates were coated with peptide conjugated to BSA by another coupling agent. Peptides 5, 4, and 7 were able to induce a high antibody response directed against the homologous peptide (Fig. 3A) , while peptides 2 and 8 gave only a weak antibody response. All antipeptide antibodies failed to react with heterologous peptides as well as with free BSA (data not shown). Antisera 2 and 5 reacted with SR, while antisera 4, 7, and 8 reacted more weakly with SR (Fig. 3B) . Similarly, sera 2, 5, 7, and 8 gave a positive response with intact cells in ELISA (Fig.  3C) , while antiserum 4 failed to react with SR present on the bacterial surface, suggesting that this peptide is not accessible or not immunodominant on the SR molecule, confirming the results obtained with free SR. Furthermore, peptide 5 elicited in rabbits antibodies to hIgG, as did (but to a lesser extent) peptides 4, 7, and 8, while peptide 2 did not (Fig. 3D) . These results confirm that the determinants responsible for the cross-reactivity between SR and hIgG which was already described (47) are located in this region of SR.
SGP-binding domain. To study the localization of the SGP-binding domain(s) on SR, the expression products of recombinant plasmids p18 D2.8, p8 PP1.4, and pSAD2 (14) were used in an adherence assay. Figure 4 C-terminal regions of SR, were very low. The fact that the binding of SGPs to free SR, to SR present on the S. mutans cell surface, and to the polypeptide encoded by plasmid p18 D2.8 was dose dependent suggests the existence of specific interactions between adhesin and SGPs and that the binding domain should be located at the N terminus of the SR protein, until aa 613. However, SGPs failed to bind to peptide 2, located in the N-terminal alanine-rich region, as well as to peptides 4, 5, 7, and 8 (data not shown). This nonbinding of SGPs to peptide 2 could be due to the fact that the 17-mer peptide represents a structure too short to enable SGP binding.
To confirm the existence of an SGP-binding domain on the SR protein, we studied, by competitive ELISA, the ability of SR-derived polypeptides and synthetic peptides to inhibit the binding of SGPs to the SR protein. The results of competition experiments, performed using a minimal saturating concentration of SGPs, are given in Fig. 5 Distribution of the alanine-rich domain and IgG-crossreacting domain among viridans streptococci. The presence of I/II-related antigens and the degree of conservation of both an alanine-rich repeat and an hIgG-cross-reacting region in 8 representative strains of the mutans group and 11 nonmutans oral streptococcus strains were determined by whole-cell ELISA with anti-SR, anti-hIgG, and anti-peptide 2, 4, 5, 7, and 8 IgG and by colony hybridization with probes I, II, III, A, and IgG (Table 3 ). All the mutans group strains except S. rattus and the 11 nonmutans streptococcal strains reacted with anti-SR and anti-IgG sera; however, some strains reacted more weakly than others, confirming the presence of cell surface SR-like molecules having epitopes cross-reactive with hIgG in all these bacteria. The results of heterologous binding demonstrate the presence and the cell surface accessibility of the antigenic determinants corresponding to peptides 5, 7, and 8 located in the hIgG-cross-reacting domain in all streptococci except S. rattus, whereas antibodies directed against peptide 4 failed to react with 13 strains and reacted only weakly with 6 strains ( -, no reactivity; +, weak reactivity; + +, strong reactivity. None of the antisera or probes reacted with E. coli HB101. bConcentrations of antisera: serum 2, 20 ,ug/ml; sera 4, 5, 7, and 8, 50 ,ug/ml; anti-SR IgG and anti-hIgG rabbit IgG, 20 pg/ml. the N-terminal SGP-binding region of SR-related proteins in oral streptococci (Table 3 ).
Reactivity of sera from patients with RD with peptides. In order to confirm the presence of anti-SR IgG antibodies in sera from RD patients and to determine the specificities of these antibodies, we tested the reactivity of 22 serum specimens from patients with RD against protein SR from S. mutans serotype f, protein P1 from S. mutans serotype c, peptide 2, and peptides 4, 5, 7, and 8 in a kinetics-dependent ELISA. Figure 6 shows that 18 serum samples from RD patients reacted strongly with SR and P1 proteins. In the same conditions, 21 serum samples from RD patients exhibited a high reactivity with peptide 5, 19 reacted with peptide 8, 17 reacted with peptide 7, and 13 reacted with peptide 4 compared with the reactivity of control sera, demonstrating that epitopes located within this region are recognized by human sera. Furthermore, the RD patient sera failed to react with peptide 2 as well as with peptides located at the C and N termini and in the proline-rich repeats (data not shown). In control experiments, immobilized peptides failed to react with rabbit anti-hIgG. Taken together, these results confirm the existence of anti-SR IgG antibodies that reacted strongly with peptides located in the hIgG-cross-reacting region of protein SR, suggesting the possible involvement of these epitopes and especially those located in peptide 5 'y2 chain. The numbers above and below every 10th amino acid refer to the position in the total sequence. Amino acid identity is shown in the line between the sequences of the SR protein and -y2 human chain, and conservative substitutions are indicated by colons. Gaps (-) were introduced to maximize regions of identity. Alignment was performed by using the algorithm of Lipman and Pearson (24) .
that amino compounds could inhibit the adherence of S. mutans to salivary agglutinin-coated hydroxyapatite (21); we cannot rule out the possibility that the inhibition of SGP binding to SR by peptide 2 is due to a lateral amino group present in some constitutive amino acids of peptide 2 (R, Q, K, N, and K). Peptide 2 was found to be immunogenic in rabbits and induces antibodies able to bind to native SR as well as to related proteins from S. mutans serotypes c and e in a whole-cell ELISA; however, anti-peptide 2 antibodies bind weakly or not at all to various oral mutans and nonmutans streptococci. These results are confirmed by colony hybridization analysis using probe A covering the third alanine-rich tandem repeat which hybridizes under high-stringency conditions with S. mutans serotypes c, e, and f; less strongly with strains of S. downei, S. millen, S. anginosus, S. intermedius, S. salivarius, and S. sanguis; and not at all with strains of S. cricetus, S. sobrinus, S. anginosus, S. constellatus, S. intermedius, S. mitis, and S. gordonii. These results indicate that a moderate degree of homology between species exists in this region and are similar to those obtained by Ma et al. (26) , who showed that the 5'-terminal region of the pac gene appears to be less conserved than the 3'-terminal domain in various oral streptococci, and those of Demuth et al. (10) Although peptides 7 and 8, corresponding to the C-terminal part of the putative hIgG-cross-reacting region, were predicted to be hidden, they were recognized by anti-SR antibodies. Peptide 7 and, to a lesser extent, peptide 8 were also able to induce antibodies which reacted with homologous peptide, SR, whole S. mutans cells, and hIgG. Furthermore, rabbit anti-hIgG antibodies and almost all RD patient sera, which reacted strongly with protein SR from S. mutans serotype f and protein P1 from S. mutans serotype c, showed a high positive reaction with peptides 5 and 8 and reacted more weakly with peptides 7 and 4. Both rabbit anti-hIgG antibodies and RD sera failed to react with peptides located along the SR sequence but on the outside of this region. A DNA probe which encoded residues 973 to 1087 of the SR molecule hybridized with DNA from all mutans streptococci except S. rattus and all nonmutans oral streptococci, including strains of S. millen, S. anginosus, S. constellatus, S. intermedius, S. mitis, S. salivanus, S. sanguis, and S. gordonii. These results confirm the results of an early study of Ma et al. (26) which showed that the 3'-terminal region of the spaP gene appears well conserved in the mutans group as well as in a variety of nonmutans alpha-hemolytic streptococci. Furthermore, primary amino acid sequence alignment analysis of the products of the cloned and sequenced I/II protein gene confirms that the sequence corresponding to aa 948 to 1028 is highly conserved within S. mutans serotypes c and f, S. sobnnus serotype g, and S. sanguis M5 (Fig. 7) . These results confirm the location of the computer-predicted hIgG-cross-reacting region within protein SR as well as the presence of anti-SR antibodies in sera from RD patients. Therefore, the immunogenicity and the ubiquity among oral viridans streptococci of epitopes located within this region implicate these epitopes, especially those corresponding to peptides 5 and 8, in the synthesis of anti-IgG antibodies in humans. Such results may be of substantial significance, since they imply that immunization with I/II-related antigens may also cause in humans enhancement of anti-IgG antibodies.
In conclusion, we have confirmed that the epitope corresponding to peptide 2 is involved in SGP binding and that epitopes corresponding to peptides 5 and 8 could be involved in the induction of anti-IgG antibody synthesis. Our results concerning peptide 2 are in accordance with recent data of Crowley et al. (8) showing that a mutant expressing a truncated P1 molecule that includes the A region retains the VOL. 62, 1994 on August 28, 2017 by guest http://iai.asm.org/ Downloaded from ability to aggregate and is totally lacking the ability to adhere, whereas a soluble recombinant A-region polypeptide can effectively achieve inhibition of adherence. Therefore, immunization with peptides located in the saliva-aggregating domain of I/II-related antigens, which is probably involved in the nonspecific hydrophobic interactions rather than in the specific interactions between these adhesins and SGPs, could elicit antibodies promoting specific bacterial agglutination which may help the nonimmunological clearance of oral streptococci mediated by salivary agglutinin. This could represent an alternative to immunization with peptides located in the more specific SGP adherence domain present at the C terminus of the SR protein (29) which contains the hIgG-cross-reacting domain, and a more precise identification of the functional domains in SR related antigens would be of considerable interest in the prevention of viridans streptococcal diseases.
